STEP1: Study on semaglutide STEP1: Study on semaglutide STEP1 study was recently published in the journal The New England Journal of Medicine titled Once-Weekly Semaglutide in Adults with Overweight or Obesity, authored by Professor John Wilding, Professor Rachel Batterham and other co-authors
4 Wegovy pill offers a magnitude of weight loss that no other oral GLP-1 obesity candidate has been able to duplicate in phase 3 trials, boasting an average weight loss of about 17% (16.6%), when used along with a reduced calorie diet and exercise and if all patients stayed on treatment, compared to about 3% (2.7%) for placebo
Three names that keep popping up are Mounjaro, Ozempic and Wegovy
For mild to moderate joint discomfort without red flag features, management should be guided by NICE NG226 (Osteoarthritis in over 16s: diagnosis and management) and may include: Exercise and physiotherapy , which are central to NICE-recommended management
It also suggests that MariTide might be better at helping people maintain weight loss than its competitors thanks to a longer half-life, even though its given less frequently
10.1007/s00018-014-1670-8 53 Figueroa-MndezR.Rivas-ArancibiaS
